Results 251 to 260 of about 46,091 (305)

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 2026-2035, June 2026.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk   +15 more
wiley   +1 more source

Endoscopically-detected small-intestinal lesions with dense infiltration of IgG4-positive plasma-cells. [PDF]

open access: yesClin J Gastroenterol
Goto H   +7 more
europepmc   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

open access: yesBritish Journal of Haematology, Volume 208, Issue 6, Page 2036-2046, June 2026.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler   +4 more
wiley   +1 more source

IgG4-Related Kidney Disease With Pancreatic Mass and Protein-Losing Enteropathy: A Case Report. [PDF]

open access: yesKidney Med
Jiang L   +10 more
europepmc   +1 more source

Plenary Abstracts Session & Oral Presentations

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Home - About - Disclaimer - Privacy